This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Fabry Disease
and you are
between 18 and 75
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects with mild, moderate, and severe renal impairment.

Provided treatments

  • Drug: AT1001 150 mg
Tris trial is registered with FDA with number: NCT01730469. The sponsor of the trial is Amicus Therapeutics and it is looking for 32 volunteers for the current phase.
Official trial title:
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)